Cargando…
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia. A single‐center, open‐label study evaluated the PKs of daridorexant in patients with...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604215/ https://www.ncbi.nlm.nih.gov/pubmed/34121345 http://dx.doi.org/10.1111/cts.13079 |